KyNexis
Latest round
- Series A
Last raised
- Aug 2026
Total raised
- $107M
Investors
- 4
About KyNexis
Based in Naarden, Netherlands, and 2023, and co-founded by Carol Tamminga, Robert Schwarcz, and Kees Been is the CEO.V. operates as a biotechnology company that offers therapeutic solutions to improve brain function, particularly cognitive impairment associated with schizophrenia.V. Kynexis is a biotechnology company developing precision therapeutics for brain diseases, with a focus on cognitive impairment associated with schizophrenia (CIAS). They are taking a biomarker-based approach to identify patients most likely to benefit from their potential new therapy, which targets KAT-II, a key enzyme in the kynurenine pathway.
Who invested in KyNexis
4 investors across 2 rounds
See all investors in KyNexis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about KyNexis
Who invested in KyNexis?
KyNexis has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has KyNexis raised?
KyNexis has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did KyNexis last raise money?
KyNexis's most recent round on record is a Series A, in Aug 2026.
What does KyNexis do?
Based in Naarden, Netherlands, and 2023, and co-founded by Carol Tamminga, Robert Schwarcz, and Kees Been is the CEO.
Where is KyNexis headquartered?
KyNexis is headquartered in Naarden, Netherlands.
Which VCs invest in companies like KyNexis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at KyNexis's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like KyNexis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.